Cite
Retraction notice to "Notoginsenoside R1 suppresses miR-301a via NF-κB pathway in lipopolysaccharide-treated ATDC5 cells" [Experimental and Molecular Pathology 112 (2020) 104355].
MLA
Dong, Yan, et al. “Retraction Notice to ‘Notoginsenoside R1 Suppresses MiR-301a via NF-ΚB Pathway in Lipopolysaccharide-Treated ATDC5 Cells’ [Experimental and Molecular Pathology 112 (2020) 104355].” Experimental & Molecular Pathology, vol. 126, June 2022, p. N.PAG. EBSCOhost, https://doi.org/10.1016/j.yexmp.2022.104774.
APA
Dong, Y., Yan, X., Yang, X., Yu, C., Deng, Y., Song, X., & Zhang, L. (2022). Retraction notice to “Notoginsenoside R1 suppresses miR-301a via NF-κB pathway in lipopolysaccharide-treated ATDC5 cells” [Experimental and Molecular Pathology 112 (2020) 104355]. Experimental & Molecular Pathology, 126, N.PAG. https://doi.org/10.1016/j.yexmp.2022.104774
Chicago
Dong, Yan, Xia Yan, Xirui Yang, Chunyan Yu, Yao Deng, Xiaoli Song, and Lei Zhang. 2022. “Retraction Notice to ‘Notoginsenoside R1 Suppresses MiR-301a via NF-ΚB Pathway in Lipopolysaccharide-Treated ATDC5 Cells’ [Experimental and Molecular Pathology 112 (2020) 104355].” Experimental & Molecular Pathology 126 (June): N.PAG. doi:10.1016/j.yexmp.2022.104774.